Sign Out
Concomitant use of memantine with alkalinizing agents that increase urine pH (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) results in decreased memantine clearance with resulting increases in adverse effects.
Concomitant administration of memantine with a fixed combination of hydrochlorothiazide and triamterene did not affect bioavailability of either memantine or triamterene and maximum plasma concentrations and AUC of hydrochlorothiazide decreased by only 20%.
Concomitant administration of memantine with other NMDA antagonists (e.g., amantadine, ketamine, dextromethorphan) has not been systematically evaluated. Use with caution.
Concomitant use of memantine with the acetylcholinesterase inhibitor donepezil did not affect the pharmacokinetics of either drug or substantially alter acetylcholinesterase inhibition by donepezil.
